Published in Lancet on December 12, 2009
Fabry disease. Orphanet J Rare Dis (2010) 3.48
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med (2013) 1.96
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis (2011) 1.57
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Drug Des Devel Ther (2015) 1.53
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. Orphanet J Rare Dis (2015) 1.41
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis (2013) 1.23
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet (2015) 1.16
Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One (2011) 1.15
Genetic susceptibility to ischemic stroke. Nat Rev Neurol (2011) 1.12
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis (2011) 1.11
Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther (2011) 1.09
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med (2012) 1.07
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol (2014) 1.07
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis (2014) 1.06
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis (2011) 1.04
Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol (2010) 1.03
Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci (2012) 1.00
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol (2012) 0.91
Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS One (2013) 0.91
Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis (2014) 0.90
Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene. PLoS One (2013) 0.90
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. JIMD Rep (2012) 0.89
Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys. Mol Med (2012) 0.86
New information on the genetics of stroke. Curr Neurol Neurosci Rep (2011) 0.85
Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open (2012) 0.84
Enzyme replacement therapy for Fabry's disease. Lancet (2010) 0.82
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ (2012) 0.80
Hypertrophic cardiomyopathy: The need for randomized trials. Glob Cardiol Sci Pract (2013) 0.80
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Fail Rev (2015) 0.80
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. JIMD Rep (2011) 0.78
Urine bikunin as a marker of renal impairment in Fabry's disease. Biomed Res Int (2013) 0.78
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep (2015) 0.78
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up. J Am Soc Nephrol (2015) 0.77
Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genet Med (2015) 0.77
Clinical studies in lysosomal storage diseases: Past, present, and future. Rare Dis (2013) 0.77
Early cardiac changes in children with anderson-fabry disease. JIMD Rep (2013) 0.76
Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease. Eur Heart J Cardiovasc Imaging (2015) 0.76
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis (2016) 0.76
Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC Nephrol (2014) 0.76
Therapeutic approaches for lysosomal storage diseases. Ther Adv Endocrinol Metab (2010) 0.76
Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey. Int J Mol Sci (2016) 0.75
Genetic stroke syndromes. Continuum (Minneap Minn) (2014) 0.75
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa. JIMD Rep (2015) 0.75
Enzyme therapy for Fabry's disease: registered for success? Lancet (2009) 0.75
Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy. Int J Med Sci (2016) 0.75
Enzyme replacement therapy for Fabry's disease. Lancet (2010) 0.75
Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis. J Hum Genet (2016) 0.75
Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis (2015) 0.75
Fabry's disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep (2012) 0.75
Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease. J Hum Genet (2015) 0.75
A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. BMC Neurol (2017) 0.75
Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. Lupus (2013) 0.75
Villa Metabolica - a center of excellence for the diagnosis and treatment of lysosomal storage disorders. Wien Med Wochenschr (2010) 0.75
Therapeutic Strategies Targeting Inherited Cardiomyopathies. Curr Heart Fail Rep (2017) 0.75
Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events. Mol Genet Metab Rep (2017) 0.75
[Fabry disease : diagnosis and treatment]. Schmerz (2012) 0.75
Case report: Long-term outcome post-heart transplantation in a woman with Fabry's disease. J Inherit Metab Dis (2010) 0.75
Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy. J Inherit Metab Dis (2014) 0.75
Newborn screening and renal disease: where we have been; where we are now; where we are going. Pediatr Nephrol (2011) 0.75
Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. PLoS One (2017) 0.75
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Comparison of UK paediatric cardiac surgical performance by analysis of routinely collected data 1984-96: was Bristol an outlier? Lancet (2001) 5.26
Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol (1992) 4.72
Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data. Am J Epidemiol (1995) 4.62
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest (2004) 4.54
A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature (2010) 4.52
In vivo T(1rho) and T(2) mapping of articular cartilage in osteoarthritis of the knee using 3 T MRI. Osteoarthritis Cartilage (2007) 3.56
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Smoking behaviour can be predicted by neighbourhood deprivation measures. J Epidemiol Community Health (1995) 3.25
Assessment of the reproducibility of clinical coding in routinely collected hospital activity data: a study in two hospitals. J Public Health Med (1998) 3.18
A regression-based method for mapping traffic-related air pollution: application and testing in four contrasting urban environments. Sci Total Environ (2000) 3.11
INTERSALT study findings. Public health and medical care implications. Hypertension (1989) 2.69
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res (2001) 2.65
Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med (1996) 2.62
Cancer incidence near radio and television transmitters in Great Britain. II. All high power transmitters. Am J Epidemiol (1997) 2.57
Current status of zirconia used in total hip implants. J Bone Joint Surg Am (2003) 2.56
Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience (2007) 2.55
Findings of the International Cooperative INTERSALT Study. Hypertension (1991) 2.53
Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum Mol Genet (2000) 2.43
Alcohol and blood pressure: the INTERSALT study. BMJ (1994) 2.41
Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis (2005) 2.40
Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med (1995) 2.39
Cancer incidence near radio and television transmitters in Great Britain. I. Sutton Coldfield transmitter. Am J Epidemiol (1997) 2.37
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary). J Hum Hypertens (2003) 2.27
Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens (2003) 2.25
Parkinsonism among Gaucher disease carriers. J Med Genet (2004) 2.24
Chlorination disinfection byproducts in water and their association with adverse reproductive outcomes: a review. Occup Environ Med (2000) 2.22
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (2001) 2.17
A pilot study of sexual lifestyle in a random sample of the population of Great Britain. AIDS (1989) 2.13
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
Mechanical strength of repairs of the rotator cuff. J Bone Joint Surg Br (1994) 2.12
Hip damage occurs at the zone of femoroacetabular impingement. Clin Orthop Relat Res (2008) 2.06
[The isolated form of cardiac amyloidosis in the form of beginning infiltrative cardiomyopathy without restrictive physiology]. Vnitr Lek (2008) 2.05
Propofol-fentanyl anaesthesia in cardiac surgery: a comparison in patients with good and impaired ventricular function. Anaesthesia (1993) 2.04
[Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ]. Vnitr Lek (2003) 2.02
Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol (1996) 1.99
Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. Proc Natl Acad Sci U S A (1993) 1.97
Do people living near inner city main roads have more asthma needing treatment? Case control study. BMJ (1996) 1.97
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis (2009) 1.89
INTERMAP: the dietary data--process and quality control. J Hum Hypertens (2003) 1.88
Ecological and individual predictors of birthweight in a northern Finland birth cohort 1986. Paediatr Perinat Epidemiol (1997) 1.85
Urinary electrolyte excretion in 24 hours and blood pressure in the INTERSALT Study. I. Estimates of reliability. The INTERSALT Cooperative Research Group. Am J Epidemiol (1994) 1.85
An overview of randomized trials of sodium reduction and blood pressure. Hypertension (1991) 1.84
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet (2004) 1.79
Temperature, housing, deprivation and their relationship to excess winter mortality in Great Britain, 1986-1996. Int J Epidemiol (2001) 1.79
An evaluation of an electric pulp tester as a measure of analgesia in human vital teeth. J Endod (1987) 1.79
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Multidisciplinary management of Hunter syndrome. Pediatrics (2009) 1.76
Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.74
Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract (2007) 1.73
Biosynthesis of proteodermatan sulfate in cultured human fibroblasts. J Biol Chem (1984) 1.71
Microinjection and growth of bacteria in the cytosol of mammalian host cells. Proc Natl Acad Sci U S A (2001) 1.71
GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology (2011) 1.69
Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet (2005) 1.67
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys (2001) 1.67
Urinary electrolyte excretion in 24 hours and blood pressure in the INTERSALT Study. II. Estimates of electrolyte-blood pressure associations corrected for regression dilution bias. The INTERSALT Cooperative Research Group. Am J Epidemiol (1994) 1.67
Who are the 'low energy reporters' in the dietary and nutritional survey of British adults? Int J Epidemiol (1997) 1.65
Case-control study of hospital admission with asthma in children aged 5-14 years: relation with road traffic in north west London. Thorax (1999) 1.63
The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology (2004) 1.63
Estimating the incidence rate ratio in cross-sectional studies using a simple alternative to logistic regression. Ann Epidemiol (1998) 1.62
The neurogenetics of mucolipidosis type IV. Neurology (2002) 1.62
Cluster analysis and disease mapping--why, when, and how? A step by step guide. BMJ (1996) 1.62
Treatment of bilateral superior oblique tendon sheath syndrome complicating rheumatoid arthritis. Br J Ophthalmol (1980) 1.62
Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis (2000) 1.61
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet (2009) 1.61
White matter lesion severity in male and female patients with Fabry disease. Neurology (2005) 1.61
Percutaneous nonangiographic insertion of Hickman catheters in marrow transplant recipients by anesthesiologists and intensivists. Anesth Analg (1997) 1.58
Proximity to coke works and hospital admissions for respiratory and cardiovascular disease in England and Wales. Thorax (2001) 1.57
The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group. J Hum Hypertens (1989) 1.57
Total hip arthroplasty in young adults after failed triple innominate osteotomy. J Arthroplasty (2001) 1.57
Body mass index versus height and weight in relation to blood pressure. Findings for the 10,079 persons in the INTERSALT Study. Am J Epidemiol (1990) 1.57
Investigating the microenvironments of inhomogeneous soft materials with multiple particle tracking. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 1.56
Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis (2001) 1.56
Puzzling changes in cervical cancer in young women. Med J Aust (1987) 1.56
Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke (2001) 1.56
Review and meta-analysis of epidemiological associations between low/moderate doses of ionizing radiation and circulatory disease risks, and their possible mechanisms. Radiat Environ Biophys (2009) 1.55
Hemostatic changes following the modified Fontan operation (total cavopulmonary connection). Thromb Haemost (2000) 1.53
Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart (2003) 1.53
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis (2003) 1.52
Cancer incidence and mortality near the Baglan Bay petrochemical works, South Wales. Occup Environ Med (1995) 1.52
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Distinct phosphatidylinositol 3-kinase lipid products accumulate upon oxidative and osmotic stress and lead to different cellular responses. J Biol Chem (1999) 1.49
Blood pressure in four remote populations in the INTERSALT Study. Hypertension (1989) 1.48
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47